Cancer therapies converge on shared heart injury pathways, prompting a dynamic surveillance framework

A new conceptual framework published in the journal Cardio-Oncology argues that cardiovascular risk in cancer care should be tracked as a moving target rather than a fixed side effect of any single drug. The proposal, called Cardio-Oncology Surveillance States, or COSS, is presented as a mechanism-informed framework that characterises cardiovascular risk states across the cancer continuum, from diagnosis through treatment and long-term survival.

The review, published on 15 October 2026 as an open-access article, was authored by a multidisciplinary group including Aleksandra Lange, Przemysław Palka, Liam Griffiths, Melissa E. Reichelt, Walter G. Thomas and numerous clinical and scientific collaborators. Its central premise is that contemporary anticancer therapies are increasingly diverse, yet the cardiovascular toxicity they produce converges on shared myocardial, vascular, and immune–metabolic pathways.

According to the authors, this convergence matters because variability in the timing and reversibility of cardiovascular toxicity limits static, therapy-specific surveillance. A monitoring schedule tied to one drug class may miss injury that emerges late, or fail to detect early signals from a different therapy that damages the heart through the same biological route. The framework therefore links biological pathways of injury to identifiable clinical signals rather than to treatment categories alone.

COSS integrates several streams of information: clinical phenotype, treatment exposure, multimodal imaging, biomarkers, and metabolic risk. By combining these inputs, the framework aims to characterise a patient’s current cardiovascular risk state dynamically, so that monitoring intensity can be escalated when risk rises and de-escalated when it falls. This risk-adapted approach contrasts with fixed surveillance protocols applied uniformly regardless of evolving biology.

The authors emphasise that the framework is conceptual. It does not report new clinical trial results, and the published article is a peer-reviewed review paper shared early to provide faster access; the version is subject to further edits and will be replaced by the final Version of Record. Its contribution lies in organising existing knowledge about cancer–cardiovascular biology into a structure that can guide surveillance decisions.

A distinctive feature of COSS is its recognition of bidirectional cancer–cardiovascular biology. Cardiovascular disease and cancer share risk factors and biological mechanisms, and each can influence the trajectory of the other. By extending cardio-oncology beyond treatment-related toxicity, the framework positions prevention as central to long-term cardiovascular and oncologic outcomes, rather than treating heart damage solely as a downstream complication of cancer therapy.

The practical implication is a shift in how clinicians might think about monitoring. Instead of asking whether a particular chemotherapy agent requires a specific echocardiogram schedule, the framework asks which biological injury pathways are active in a given patient, which clinical signals—imaging findings, biomarker changes, metabolic indicators—reflect those pathways, and how intensively those signals should be tracked as the patient moves through treatment and survivorship.

The review’s highlights state that diverse cancer therapies converge on shared myocardial, vascular, and immune injury pathways, limiting therapy-specific surveillance approaches, and that COSS defines a dynamic, mechanism-informed framework aligning monitoring intensity with evolving biological risk. The third highlight notes that bidirectional cancer–cardiovascular biology reframes the field, positioning prevention as central to long-term outcomes.

As a conceptual contribution, the framework will require validation in clinical practice before its effects on patient outcomes can be known. The article does not present data demonstrating that mechanism-informed surveillance improves cardiovascular or cancer outcomes, and the authors do not claim such evidence. What the review offers is a structured way to connect the biology of cardiovascular injury with the clinical tools already available—imaging, biomarkers, and metabolic assessment—so that surveillance can adapt as a patient’s risk state changes across the cancer continuum.

Subject of Research: A conceptual framework for mechanism-informed cardiovascular risk surveillance across the cancer continuum

Article Title: Cardio-Oncology Surveillance States: a mechanism-informed framework for cardiovascular risk across the cancer continuum

Article References: Lange, A., Palka, P., Griffiths, L., Reichelt, M. E., Lange, J., Allen, A., Donnelly, J. E., Colosimo, M., Morton, J., Taylor, K., Jain, V., Shanavas, M., Taylor, J., Taylor, E., Andelkovic, V., Butler, J., Banh, R., Fanning, S., Nath, K., … Thomas, W. G. (2026). Cardio-Oncology Surveillance States: a mechanism-informed framework for cardiovascular risk across the cancer continuum. Cardio-Oncology. https://doi.org/10.1186/s40959-026-00577-w

Image Credits: AI Generated

DOI: 10.1186/s40959-026-00577-w

Keywords: cardio-oncology, cardiovascular toxicity, cancer therapies, surveillance framework, biomarkers, multimodal imaging, metabolic risk, prevention, risk-adapted monitoring, cancer continuum, Surveillance, States